What this is
- This study investigates the effects of on diastolic function in patients with type 2 diabetes and coronary artery disease.
- It involved 30 subjects in a randomized, double-blind, crossover design over 12 weeks.
- The primary focus was on diastolic function parameters assessed via 2D echocardiography.
Essence
- did not improve diastolic function parameters in patients with type 2 diabetes and coronary artery disease. Instead, a reduction in early diastolic annular velocities (e') was observed, potentially linked to an increase in heart rate.
Key takeaways
- treatment led to a significant reduction in average e' velocities, with a decrease of -0.57 cm/s and -0.74 cm/s in average and lateral e' velocities, respectively. This indicates a deterioration in diastolic function.
- Despite improvements in weight and metabolic factors, no significant changes were observed in other diastolic function parameters such as E/e', E/A ratio, and left atrial volume.
- An increase in heart rate of +6.16 bpm was noted after therapy, suggesting a potential mechanism for the observed decline in diastolic function.
Caveats
- The study was not powered to detect changes in diastolic function parameters, limiting the robustness of the findings. Additionally, the cohort's homogeneity may restrict the generalizability of the results.
- The increase in heart rate associated with therapy raises questions about its impact on diastolic function, but the exact relationship remains unclear.
Definitions
- diastolic dysfunction: Impaired relaxation and filling of the heart's ventricles, often leading to heart failure.
- liraglutide: A GLP-1 receptor agonist used to improve glycemic control in type 2 diabetes.
Simplified
Background
The prevalence of diastolic dysfunction in patients with type 2 diabetes mellitus (T2DM) is up to 75% and correlates with the degree of glucose dysregulation [1]. The condition is associated with factors such as overweight, hypertension, and coronary artery disease (CAD) [2]. Features of diastolic dysfunction such as impaired left ventricular (LV) relaxation, increased chamber stiffness, and increased LV filling pressure can be assessed non-invasively using 2D echocardiography [3]. Parameters of diastolic function derived from echocardiography have shown to predict mortality and hospitalization for heart failure [4, 5].
Glucagon-like peptide 1 (GLP-1) is an incretin hormone that reduces hyperglycemia, improves endothelial function, induce vasodilatory effects on arteries, and in clinical studies shown to reduce cardiovascular events, and improve cardiac function [6]. GLP-1 receptor agonists (RAs) mimic the effects of GLP-1 and is currently a well-established treatment option for T2DM [7]. GlP-1 RAs induce weight loss and improve glucometabolic factors [8], thus modulating risk factors associated with diastolic dysfunction. On this background, it is likely that treatment with GLP-1 RA would improve diastolic function.
In this randomized study, we examined the effect of the GLP-1 receptor agonist liraglutide on parameters of diastolic function in overweight patients with stable CAD, preserved left ventricular ejection fraction (LVEF), and newly diagnosed T2DM.
Methods
We designed a randomized, double-blind, placebo-controlled 12 plus 12 weeks cross over study with a 2-week washout period. In- and exclusion criteria and the outline of the trial visits have been presented previously [9, 10]. In short, we included overweight patients with stable CAD, LVEF > 40% and newly diagnosed T2D within 24 months. Patients were recruited through patient files from selected hospitals in Copenhagen (Denmark) from May 2012 to October 2014. Patients on antidiabetic treatment before the study underwent a minimum 2-week washout period before the baseline visit. All subjects underwent 2D echocardiography, blood tests, anthropometric measurements, and blood pressure measurements at the beginning and end of each period (week 0, 12, 14, and 26). Subjects, investigators, and all caregivers were blinded to the treatment sequence. Data on systolic function has been published previously [10].
Study drug
Patients who were on anti-diabetic treatment before the study underwent a minimum 2-week washout period before the first visit. Liraglutide or placebo were titrated in an identical manner in the active and placebo period, respectively: 0.6 mg liraglutide/placebo once daily (o.d.) was increased after 14 days to 1.2 mg o.d and to 1.8 mg o.d. after 28 days. All subjects had a backbone therapy of active metformin that were increased in a similar dose in both periods: 500 mg metformin twice daily was increased to 1000 mg + 500 mg after 14 days and to 1000 mg twice daily after 28 days.
2D echocardiography
The details of echocardiography protocol have been described previously [10]. In short, 2D echocardiography was performed at rest using a M5S transducer (Vivid E9, GE Vingmed Ultrasound, Horten, Norway). LVEF was calculated using the Simpson biplane method. Diastolic function parameters and their respective cut-off values were chosen as recommended in guideline [3]. Early diastolic filling velocity (E), late atrial filling velocity (A), E-wave deceleration time (EDT) and E/A ratio was assessed from the pulse wave (PW)-Doppler velocity recording of the mitral inflow. Peak early diastolic annular velocities (e′) was measured from color tissue doppler images with sample area placed in the septal, lateral, anterior and inferior parts of the mitral. Measurements was averaged from three beats. Furthermore, heart rate (HR) was measured from the ECG-recording from the echocardiography machine. Four investigators performed the echocardiography examinations (AS, OWN, OK, and PK). The off-line echocardiography analyses were performed by one observer (PK) who were blinded to the treatment protocol.
Statistical analysis
No formal sample size calculation for diastolic function parameters was performed, as the study was primarily powered to detect changes in LVEF [10]. Continuous variables were summarized as the mean ± SD or medians with interquartile ranges, and categorical variables were summarized as percentages. The per-protocol population was defined as subjects who completed both measurement series in both intervention periods. Treatment effects of liraglutide and placebo were compared by using the paired t test. The association between variables of interest was examined by using linear regression. Chi- square test was used to compare differences in categorical variables between groups. The null hypothesis was rejected for values of P (two-sided) less than 0.05. All statistical analyses were performed with Stata 13.1 (StataCorp, College Station, Texas, USA).
Results
In total, 41 subjects were randomly assigned to an intervention in this study. Screening, enrollment, and follow-up of the study population has been described previously [10]. Eleven subjects discontinued the study (2 subjects declined to participate after randomization, 9 subjects discontinued the study due to serious adverse events, intolerance to medication or other reasons). Thus, 30 subjects were available for the per protocol analyses. See Additional file 1: Figure S1.
No significant changes in other diastolic function parameters were observed: average E/eʹ, E/A ratio, Peak E velocity, Peak TR velocity, left atrial volume, deceleration time, septal eʹ velocity.
A significant increase in baseline HR after liraglutide therapy was observed (+ 6.16 bpm [95% CI 0.79 to 11.54]).
Changes in resting blood pressure and metabolic variables are shown in Additional file: Table S1. 2
| Characteristics | Total (n = 30) |
|---|---|
| Clinical characteristics | |
| Age, year | 63.1 (6.6) |
| Male Sex, n (%) | 24 (80) |
| Weight, kg | 98.6 (18.0) |
| BMI, kg/m2 | 32.0 (5.2) |
| Waist, cm | 112.2 (10.9) |
| Systolic blood pressure, mmHg | 142.7 (19.6) |
| Diastolic blood pressure, mmHg | 79.7 (10.0) |
| Heart rate, bpm | 68.6 (10.1) |
| Risk factors | |
| Smoker, n (%) | 14 (36) |
| Hypertension, n (%) | 23 (77) |
| Coronary artery disease | |
| Previous MI, n (%) | 16 (53) |
| Previous CABG, n (%) | 13 (43) |
| Previous PCI, n (%) | 16 (53) |
| Coronary stenosis, medical therapy only, n (%) | 2 (7) |
| Biochemistry | |
| Fasting blood glucose, mmol/l | 6.4 (1.4) |
| HbA1C, % | 6.3 (0.5) |
| LDL-cholesterol, mmol/l | 2.3 (0.7) |
| eGFR, ml/min | 78.3 (11.5) |
| Medication | |
| Beta blockers, n (%) | 20 (67) |
| Calcium antagonists, n (%) | 15 (50) |
| ACE-I, ARB, n (%) | 20 (67) |
| Statins, n (%) | 29 (97) |
| Ivabradine, n (%) | 1 (3) |
| Diuretics, n (%) | 10 (33) |
| Aspirin, n (%) | 29 (97) |
| Pre-study diabetes medication | |
| Biguanide (metformin), n (%) | 12 (40) |
| Sulfonylurea, n (%) | 1 (3.3) |
| Diet and lifestyle therapy only, n (%) | 18 (60) |
| Parameters | Total (n = 30) |
|---|---|
| LVMI, gram/m2 | 83.4 (23.3) |
| RWT, cm | 0.32 (0.1) |
| Left atrial volume index, ml/m2 | 29.3 (8.3) |
| E/A ratio | 0.95 (0.1) |
| Peak E velocity, m/s | 0.8 (0.2) |
| Deceleration time, ms | 239.22 (42.3) |
| Average E/eʹ | 15.36 (6.4) |
| Lateral eʹ velocity, cm/s | 6.59 (2.4) |
| Septal eʹ velocity, cm/s | 5.1 (1.4)* |
| Peak TR velocity, m/s | 2.2 (0.5)** |
| Average eʹ, cm/s | 5.7 (1.6) |
| Systolic function | |
| LVEF, baseline, % | 58.9 (7.2) |
| Average s’ velocity, cm/s | 6.0 (1.3) |
| GLS, % | 16.4 (2.9) |
| Number of subjects with signs of diastolic dysfunction | |
| Average E/eʹ > 14, n (%) | 14 (46.7%) |
| Lateral eʹ velocity < 10 cm/s or septal eʹ velocity < 7 cm/s, n (%) | 29 (96.7%) |
| Peak TR velocity > 2.8 m/s | 2 (7.4%)** |
| Left atrial volume index > 34 ml/m2 | 9 (30%) |
| Before liraglutide | After liraglutide | Before placebo | After placebo | N for treatment effect | Treatment effect for liraglutide | Treatment effect for placebo | Difference (95% CI) | p-value | |
|---|---|---|---|---|---|---|---|---|---|
| Diastolic function parameters | |||||||||
| Average E/eʹ | 14.53 (5.76) | 14.23 (5.55) | 15.28 (6.21) | 14.5 (5.98) | 29 | − 0.20 (2.61) | − 0.85 (3.44) | 0.65 (− 0.86 to 2.16) | 0.386 |
| Lateral eʹ velocity, cm/s | 7.02 (2.15) | 6.62 (2.11) | 6.52 (2.62) | 6.85 (1.98) | 30 | − 0.40 (1.29) | 0.33 (1.55) | − 0.74 (− 1.32 to − 0.15) | 0.016 |
| Septal eʹ velocity, cm/s | 5.34 (1.32) | 5.01 (1.37) | 5.24 (1.52) | 5.3 (1.44) | 29 | − 0.31 (0.94) | − 0.03 (1.05) | − 0.28 (− 0.85 to 0.29) | 0.326 |
| Average eʹ, cm/s | 6.11 (1.55) | 5.62 (1.47) | 5.76 (1.72) | 5.84 (1.54) | 30 | − 0.49 (0.96) | 0.08 (0.95) | − 0.57 (− 1.05 to − 0.08) | 0.023 |
| Peak TR velocity, m/s | 2.2 (0.55) | 2.09 (0.6) | 2.23 (0.52) | 2.17 (0.53) | 26 | − 0.06 (0.49) | − 0.09 (0.27) | 0.03 (− 0.15 to 0.2) | 0.732 |
| Left atrial volume index, ml/m2 | 30.36 (9.04) | 26.42 (9.34) | 29.78 (8.14) | 26.77 (8.88) | 30 | − 3.95 (5.59) | − 3.01 (7.9) | − 0.94 (− 4.76 to 2.89) | 0.621 |
| Other measures of diastolic function and heart rate | |||||||||
| E/A ratio | 1.06 (0.57) | 0.89 (0.22) | 0.94 (0.25) | 1.02 (0.51) | 29 | − 0.18 (0.51) | 0.08 (0.33) | − 0.26 (− 0.55 to 0.03) | 0.082 |
| Mitral valve peak E velocity, cm/s | 0.83 (0.19) | 0.75 (0.16) | 0.8 (0.16) | 0.78 (0.17) | 29 | − 0.08 (0.13) | − 0.02 (0.12) | − 0.06 (− 0.13 to 0.02) | 0.142 |
| Deceleration time, milliseconds | 242.55 (49.71) | 234.03 (50.97) | 247.95 (48.19) | 246.83 (61.02) | 29 | − 9.90 (51.06) | 0.07 (58.8) | − 9.96 (− 39.78 to 19.85) | 0.499 |
| Heart rate, bpm | 67.67 (12.59) | 74.28 (13.08) | 68.03 (11.56) | 68.48 (9.25) | 30 | 6.61 (10.63) | 0.45 (8.12) | 6.16 (0.79 to 11.54) | 0.026 |
Regression analyses
| β-coefficient | 95% CI | p-value | |
|---|---|---|---|
| Dependent variable | |||
| Changes in average eʹ | |||
| Univariate | − 0.57 | − 1.06 to − 0.07 | 0.025 |
| Adjusted for changes in HR | − 0.48 | − 0.995 to 0.043 | 0.071 |
| Changes in lateral eʹ | |||
| Univariate | − 0.74 | − 1.47 to 0.002 | 0.051 |
| Adjusted for changes in HR | − 0.73 | − 1.51 to 0.06 | 0.068 |
| Changes in septal eʹ | |||
| Univariate | − 0.28 | − 0.80 to 0.24 | 0.289 |
| Adjusted for changes in HR | − 0.13 | − 0.67 to 0.41 | 0.63 |
| Dependent variable | Independent variable | Placebo | Liraglutide | ||||
|---|---|---|---|---|---|---|---|
| β | R2 | p-value | β | R2 | p-value | ||
| ΔAverage eʹ | Δheart rate | − 0.012 | 0.01 | 0.602 | − 0.016 | 0.033 | 0.339 |
| ΔAverage eʹ | Δweight | 0.054 | 0.022 | 0.437 | < 0.001 | < 0.001 | 0.993 |
| ΔAverage eʹ | ΔHbA1C | − 0.010 | < 0.001 | 0.981 | 0.147 | 0.003 | 0.783 |
| ΔAverage eʹ | ΔSystolic BP | 0.006 | 0.01 | 0.603 | 0.002 | 0.001 | 0.882 |
| ΔAverage eʹ | ΔDiastolic BP | − 0.010 | 0.008 | 0.639 | − 0.023 | 0.081 | 0.127 |
| Lateral eʹ velocity | Δheart rate | < 0.001 | < 0.001 | 0.993 | − 0.002 | < 0.001 | 0.93 |
| Lateral eʹ velocity | Δweight | 0.008 | < 0.001 | 0.944 | − 0.040 | 0.012 | 0.572 |
| Lateral eʹ velocity | ΔHbA1C | − 0.002 | < 0.001 | 0.997 | 0.126 | 0.001 | 0.861 |
| Lateral eʹ velocity | ΔSystolic BP | 0.014 | 0.02 | 0.459 | − 0.014 | 0.036 | 0.319 |
| Lateral eʹ velocity | ΔDiastolic BP | − 0.016 | 0.009 | 0.628 | − 0.026 | 0.061 | 0.189 |
| Septal eʹ velocity | Δheart rate | − 0.029 | 0.044 | 0.277 | − 0.023 | 0.07 | 0.167 |
| Septal eʹ velocity | Δweight | 0.111 | 0.074 | 0.154 | 0.021 | 0.006 | 0.685 |
| Septal eʹ velocity | ΔHbA1C | 0.084 | 0.001 | 0.857 | 0.452 | 0.028 | 0.388 |
| Septal eʹ velocity | ΔSystolic BP | 0 | < 0.001 | 0.983 | − 0.007 | 0.018 | 0.489 |
| Septal eʹ velocity | ΔDiastolic BP | − 0.015 | 0.017 | 0.502 | − 0.025 | 0.107 | 0.084 |
| Average E/eʹ | Δheart rate | − 0.063 | 0.023 | 0.423 | − 0.061 | 0.054 | 0.225 |
| Average E/eʹ | Δweight | 0.118 | 0.008 | 0.631 | 0.241 | 0.107 | 0.083 |
| Average E/eʹ | ΔHbA1C | 2.889 | 0.135 | 0.046 | − 1.072 | 0.02 | 0.461 |
| Average E/eʹ | ΔSystolic BP | − 0.008 | 0.002 | 0.836 | − 0.010 | 0.004 | 0.735 |
| Average E/eʹ | ΔDiastolic BP | − 0.045 | 0.014 | 0.539 | 0.055 | 0.064 | 0.185 |
Discussion
In this double-blind, placebo-controlled study, we examined the effect of 12 weeks of liraglutide treatment on diastolic function parameters as assessed by 2D echocardiography. We demonstrated that liraglutide did not improve any diastolic parameters. Instead, we observed a reduction in eʹ suggesting a mild worsening of diastolic function, that may be attributed to an increase in HR induced by liraglutide therapy.
Obesity and T2DM are associated with diastolic dysfunction [11]. Accordingly, weight loss and improvement in metabolic factors have shown to improve parameters of diastolic function [12]. The baseline data in our population revealed a high proportion of subjects that displayed one or more abnormal diastolic function parameters. However, despite significant weight loss and improvement in glucometabolic parameters during the liraglutide period, we did not find any improvement in diastolic function parameters. Instead, eʹ, a commonly used marker for diastolic function deteriorated. It is not clear if this seemingly worse eʹ represents a true worsening of diastolic function or is a result of the increased heart rate secondary to liraglutide. We observed a significant negative association between liraglutide treatment and average eʹ in our regression analyses. Furthermore, when adjusting for the HR changes, the association between eʹ and liraglutide became non-significant suggesting that the increase in resting HR during liraglutide therapy led to a reduced e’.
Previous studies have shown the inverse relation between HR and diastolic function. Esfandiari et al. showed in a small cohort of subjects with and without HF that atrial pacing impaired diastolic function parameters [13]. Burns et al. showed in 15 subjects that accelerated HR by atrial pacing, induced a significant decrease in e’ [14]. However, we did not find any direct correlation between changes in HR and changes in average eʹ in our study. Nevertheless, the HR increase associated with liraglutide has been of concern, namely in subjects with heart failure with reduced ejection fraction [15–17]. An increase in death or rehospitalization for heart failure was observed in subjects with T2DM and heart failure with reduced ejection fraction [16]. Whether the adverse events were due to any detrimental effect of liraglutide on myocardial relaxation or due to HR increase was not assessed in that study.
Effect of GLP-1 RA on diastolic function in previous trials are in line with our present findings. A randomized, placebo-controlled study of 33 patients with T2DM patients showed that liraglutide blunted the effect of supervised training on diastolic function (eʹ), which in the placebo groups improved [18]. In a randomized open-label study, patients with T2DM and subclinical heart failure did not improve diastolic function parameters after 18 weeks of liraglutide therapy when compared to glimepiride treatment [19]. In a small study of 23 patients LV filling pressure was improved after liraglutide therapy, but no effect on myocardial relaxation (eʹ) was seen [20]. Exenatide therapy did not improve either exercise capacity or diastolic function in a randomized, placebo-controlled study [21]. The LIVE study examined the effect of liraglutide on LV function in subjects with LVEF ≤ 40% [15]. A small improvement in E/eʹ was indeed observed; however, the authors note that the clinical relevance of these findings was unclear [15, 22]. In a prospective, observational, non-randomized study, 6 months of liraglutide therapy improved several diastolic function parameters [23]. However, the study was not randomized or blinded and did not have a prober control-group. In a systemic review and network metanalysis no clear signal on e’ was found in GLP-1 RA studies [24].
Potential strength and limitations of the study should be mentioned. The use of crossover design reduced the within-patient variation thus granting appropriate power in our study to address the primary endpoints. We did not perform a power calculation with diastolic function parameters as the study was primarily powered to detect changes in LVEF [10]. Furthermore, carry over effects were not assessed. Thus, the data presented here are exploratory analyses and should be regarded as hypothesis-generating. We analyzed only echocardiographic measures of diastolic dysfunction. Thus, any improvement in parameters associated with diastolic dysfunction, such as dyspnea or natriuretic peptides, were not evaluated in this study. The homogeneity of the cohort limits the application of our results to other patient groups such as patients with severe heart failure, patients with long-standing diabetes with poor glycemic control, or patients with severe CAD.
We previously demonstrated that liraglutide did not improve systolic function [10]. Our current findings suggest that liraglutide does not improve diastolic function either. Instead, we observed deterioration of one of the parameters of diastolic function. As previously described, 48-h HR monitoring revealed an increase in HR of 8.1 bpm after liraglutide therapy when compared to placebo [25]. Although, the resting HR during echocardiography described here were of smaller magnitude, our analyses suggest that the increase in HR may explain this deterioration in diastolic function. If so, HR-limiting medications, such as beta-blockers or sinus node inhibitors, in combination with GLP-1 RAs may improve or at least reduce deterioration of diastolic function parameters. Despite our findings suggesting deterioration of diastolic function, it was demonstrated in the LEADER study [7], that liraglutide had an overall beneficial effect on cardiovascular outcome. This may be due to the pleiotropic effect of liraglutide and GLP-1 RAs in general [26].
Conclusions
In conclusion, our study showed that liraglutide therapy do not improve any diastolic function parameters in subjects with T2DM, CAD, and preserved LVEF. Instead, we observed a deterioration in e’ that may be mediated by the HR increase induced by liraglutide therapy.
Supplementary Information
Additional file 1: Figure S1. Screening, enrollment, and follow-up of the study population.Additional file 2: Table S1. Effect of liraglutide versus placebo on blood pressure and metabolic variables. Table S2. Regression coefficients (β), R-squared values and p-values from linear regression analysis.